These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 32401685)

  • 1. Safety of Immune Checkpoint Inhibitors in Patients With Pre-Existing Inflammatory Bowel Disease and Microscopic Colitis.
    Grover S; Ruan AB; Srivoleti P; Giobbie-Hurder A; Braschi-Amirfarzan M; Srivastava A; Buchbinder EI; Ott PA; Kehl KL; Awad MM; Hodi FS; Rahma OE
    JCO Oncol Pract; 2020 Sep; 16(9):e933-e942. PubMed ID: 32401685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics and outcomes of cancer patients with pre-existing microscopic colitis after exposure to PD-1 and PD-L1 inhibitors.
    Thomas AR; Liu C; Tong YT; Tan D; Altan M; Siddiqui BA; Shatila M; Khan A; Thomas AS; Wang Y
    J Cancer Res Clin Oncol; 2023 Jul; 149(8):5429-5436. PubMed ID: 36451045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incidence of immune checkpoint inhibitor-mediated diarrhea and colitis (imDC) in patients with cancer and preexisting inflammatory bowel disease: a propensity score-matched retrospective study.
    Sleiman J; Wei W; Shah R; Faisal MS; Philpott J; Funchain P
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34158318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review with meta-analysis: safety and tolerability of immune checkpoint inhibitors in patients with pre-existing inflammatory bowel diseases.
    Meserve J; Facciorusso A; Holmer AK; Annese V; Sandborn WJ; Singh S
    Aliment Pharmacol Ther; 2021 Feb; 53(3):374-382. PubMed ID: 33314269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review.
    Nakane T; Mitsuyama K; Yamauchi R; Kakuma T; Torimura T
    Kurume Med J; 2023 Jul; 68(2):43-52. PubMed ID: 37100606
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint inhibitor gastritis is often associated with concomitant enterocolitis, which impacts the clinical course.
    Haryal A; Townsend MJ; Baskaran V; Srivoleti P; Giobbie-Hurder A; Sack JS; Isidro RA; LeBoeuf NR; Buchbinder EI; Hodi FS; Grover S
    Cancer; 2023 Feb; 129(3):367-375. PubMed ID: 36377339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of immune checkpoint inhibitor in patients with cancer and pre-existing inflammatory bowel disease: Recommendations from the GETAID.
    Amiot A; Laharie D; Malamut G; Serrero M; Poullenot F;
    Dig Liver Dis; 2022 Sep; 54(9):1162-1167. PubMed ID: 35842365
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of Immune Checkpoint Inhibitors in Patients With Pre-established Inflammatory Bowel Diseases: Retrospective Case Series.
    Braga Neto MB; Ramos GP; Loftus EV; Faubion WA; Raffals LE
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1285-1287.e1. PubMed ID: 32565289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease exacerbation is common in inflammatory bowel disease patients treated with immune checkpoint inhibitors for malignancy.
    Rubin SJS; Balabanis T; Gubatan J; Habtezion A
    World J Clin Cases; 2022 Feb; 10(6):1787-1794. PubMed ID: 35317167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy.
    Halle BR; Betof Warner A; Zaman FY; Haydon A; Bhave P; Dewan AK; Ye F; Irlmeier R; Mehta P; Kurtansky NR; Lacouture ME; Hassel JC; Choi JS; Sosman JA; Chandra S; Otto TS; Sullivan R; Mooradian MJ; Chen ST; Dimitriou F; Long G; Carlino M; Menzies A; Johnson DB; Rotemberg VM
    J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34635495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel Disease.
    Abu-Sbeih H; Faleck DM; Ricciuti B; Mendelsohn RB; Naqash AR; Cohen JV; Sellers MC; Balaji A; Ben-Betzalel G; Hajir I; Zhang J; Awad MM; Leonardi GC; Johnson DB; Pinato DJ; Owen DH; Weiss SA; Lamberti G; Lythgoe MP; Manuzzi L; Arnold C; Qiao W; Naidoo J; Markel G; Powell N; Yeung SJ; Sharon E; Dougan M; Wang Y
    J Clin Oncol; 2020 Feb; 38(6):576-583. PubMed ID: 31800340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.
    Terrin M; Migliorisi G; Dal Buono A; Gabbiadini R; Mastrorocco E; Quadarella A; Repici A; Santoro A; Armuzzi A
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511260
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dietary Considerations for Inflammatory Bowel Disease Are Useful for Treatment of Checkpoint Inhibitor-Induced Colitis.
    Saha A; Dreyfuss I; Sarfraz H; Friedman M; Markowitz J
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of appendectomy as a potential risk factor for immune checkpoint inhibitor-associated enterocolitis.
    Krasnow NA; Chute DF; Falade AS; North CM; Reynolds KL; Dougan ML
    Immunotherapy; 2023 Aug; 15(12):913-920. PubMed ID: 37292001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Use of Proton Pump Inhibitors Is Associated With an Increased Risk of Immune Checkpoint Inhibitor Colitis in Renal Cell Carcinoma.
    Yin J; Elias R; Peng L; Levonyak N; Asokan A; Christie A; Kubiliun N; Brugarolas J; Hammers HJ
    Clin Genitourin Cancer; 2022 Jun; 20(3):260-269. PubMed ID: 35277350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of immune checkpoint inhibitors in patients with cancer and pre-existing autoimmune disease.
    Alexander S; Swami U; Kaur A; Gao Y; Fatima M; Ginn MM; Stein JE; Grivas P; Zakharia Y; Singh N
    Ann Transl Med; 2021 Jun; 9(12):1033. PubMed ID: 34277833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitor Enterocolitis vs Idiopathic Inflammatory Bowel Disease.
    Shirwaikar Thomas A; Hanauer S; Wang Y
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):878-890. PubMed ID: 36270617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Checkpoint Inhibitor Colitis Shows Drug-Specific Differences in Immune Cell Reaction That Overlap With Inflammatory Bowel Disease and Predict Response to Colitis Therapy.
    Lo YC; Price C; Blenman K; Patil P; Zhang X; Robert ME
    Am J Clin Pathol; 2021 Jul; 156(2):214-228. PubMed ID: 33555016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune Checkpoint Inhibitor-associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies.
    Tran AN; Wang M; Hundt M; Chugh R; Ohm J; Grimshaw A; Ciarleglio M; Hung KW; Proctor DD; Price CC; Laine L; Al-Bawardy B
    J Immunother; 2021 Oct; 44(8):325-334. PubMed ID: 34380976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of Patients With Immune Checkpoint Inhibitor-Induced Enterocolitis: A Systematic Review.
    Collins M; Soularue E; Marthey L; Carbonnel F
    Clin Gastroenterol Hepatol; 2020 May; 18(6):1393-1403.e1. PubMed ID: 32007539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.